We are live on ! Find out more
DC

Decheng Capital Portfolio holdings

AUM $732M
1-Year Est. Return 275.56%
This Fund
S&P 500
This Quarter Est. Return
+15.93%
1 Year Est. Return
+275.56%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$732M
AUM Growth
+$70.4M
Cap. Flow
-$12.6M
Cap. Flow %
-1.72%
Top 10 Hldgs %
98.08%
Holding
15
New
1
Increased
–
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
TNGX icon
Tango Therapeutics
TNGX
+$494K

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$5.96M
2
NAMS icon
NewAmsterdam Pharma
NAMS
+$4.88M
3
KRYS icon
Krystal Biotech
KRYS
+$1.89M
4
RCUS icon
Arcus Biosciences
RCUS
+$322K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.59B
$453M 61.87%
6,371,669
– –
NUVB icon
2
Nuvation Bio
NUVB
$2.34B
$147M 20.15%
25,954,439
– –
AARD
3
Aardvark Therapeutics
AARD
$127M
$22.6M 3.08%
3,917,299
– –
ACRS icon
4
Aclaris Therapeutics
ACRS
$885M
$21.4M 2.92%
4,041,736
– –
UPB
5
Upstream Bio Inc
UPB
$366M
$18.9M 2.58%
2,724,868
– –
RCUS icon
6
Arcus Biosciences
RCUS
$3.72B
$14.3M 1.96%
464,779
-13,040
-3% -$322K
EQ icon
7
Equillium
EQ
$152M
$14.2M 1.94%
4,447,308
– –
RVMD icon
8
Revolution Medicines
RVMD
$44.6B
$9.86M 1.35%
52,667
-40,833
-44% -$5.96M
LYEL icon
9
Lyell Immunopharma
LYEL
$356M
$9.72M 1.33%
692,050
– –
BYSI icon
10
BeyondSpring
BYSI
$27.4M
$6.65M 0.91%
3,800,702
– –
ZNTL icon
11
Zentalis Pharmaceuticals
ZNTL
$360M
$6.42M 0.88%
1,323,327
– –
NAMS icon
12
NewAmsterdam Pharma
NAMS
$3.1B
$5.99M 0.82%
176,887
-148,170
-46% -$4.88M
PYXS icon
13
Pyxis Oncology
PYXS
$269M
$984K 0.13%
326,810
– –
TNGX icon
14
Tango Therapeutics
TNGX
$3.94B
$625K 0.09%
+20,000
New +$494K
KRYS icon
15
Krystal Biotech
KRYS
$10.4B
– –
-7,300
Closed -$1.89M

Similar funds

HEIP
Hudson Edge Investment Partners Jersey City, New Jersey $732M AUM 23.32% 1-Year Est. Return
TCP
ThornTree Capital Partners Boston, Massachusetts $731M AUM 30.12% 1-Year Est. Return
MCM
Morton Capital Management Calabasas, California $731M AUM 20.62% 1-Year Est. Return
LS
Liquid Strategies Atlanta, Georgia $732M AUM 17.42% 1-Year Est. Return
MHS
M Holdings Securities Portland, Oregon $731M AUM 34.87% 1-Year Est. Return
GHAM
Gilman Hill Asset Management New Canaan, Connecticut $731M AUM 19.41% 1-Year Est. Return
MIOT
Massachusetts Institute of Technology Cambridge, Massachusetts $733M AUM 24.57% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $733M AUM 11.32% 1-Year Est. Return

Decheng Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Decheng Capital held 15 positions worth $732M, up 11% from $661M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Decheng Capital's Q2 2026 filing shows 1 new, 3 reduced and 1 closed positions. Its largest new stake was Tango Therapeutics: 20,000 shares worth $625K. The largest sale was Revolution Medicines, an estimated $5.96M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Decheng Capital's largest Q2 2026 buy was Tango Therapeutics: 20,000 shares worth $625K.
  • Decheng Capital's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $5.96M.
  • Decheng Capital fully exited Krystal Biotech in Q2 2026, selling an estimated $1.89M.
  • Decheng Capital's ten largest holdings make up 98% of its $732M portfolio in Q2 2026.
  • Decheng Capital opened 1 new position and closed 1 in Q2 2026.
  • Decheng Capital's portfolio value rose 11% quarter-over-quarter to $732M.

Based on Decheng Capital's 13F filing for Q2 2026, filed 14 Aug 2026.